Patients undergoing percutaneous coronary intervention (PCI) for coronary artery disease (CAD) are administered antiplatelet therapy to reduce the rate of incidence of major adverse cardiac events [1, 2] . Dual antiplatelet therapy with aspirin and clopidogrel has emerged as the gold standard treatment for patients treated with drugeluting stents (DES) for the prevention of stent thrombosis [2] [3] [4] . However, there is variability in the patients' response to antiplatelet therapy, and some patients continue to have ischemic recurrences, including stent thrombosis [2, 5] . Although, the pathophysiology of recurrent ischemic events is multifactorial, resistance to aspirin and clopidogrel, which has been reported in a significant Background: Dual therapy with aspirin and clopidogrel has emerged as the gold standard therapy for patients treated with drug-eluting stents (DES). However, there is variability in patients' responses to this antiplatelet therapy, and some patients continue to show ischemic recurrences after therapy. The purpose of the study was to compare the simultaneously obtained results of various plateletfunction tests for assessing the prevalence of antiplatelet resistance in coronary artery disease patients undergoing DES therapy.
INTRODUCTION
proportion of CAD patients undergoing PCI, has been shown to be a major precipitating factor [6] [7] [8] [9] . There is no consensus on the characterization of aspirin and clopidogrel resistance, and its prevalence remains unclear [10, 11] . This resistance is generally accepted to be characterized by incomplete suppression of platelet aggregation, as assessed by platelet-function tests. Currently, platelet function can be measured using numerous plateletfunction tests, which can be of great value for determining the efficacy of antiplatelet drugs. However, the results of antiplatelet tests are highly dependent on the test used. Various platelet-function tests show great variability in differentiating between resistant and sensitive patients [12] . Therefore, the purpose of this study was to compare the simultaneously obtained results of various platelet-function tests for the assessing the prevalence of aspirin and clopidogrel resistance in CAD patients undergoing PCI.
MATERIALS AND METHODS

Patients
Sixty-six patients scheduled to undergo DES therapy at Dong-a University Hospital between March 2009 and December 2009 were included. Angiography revealed coronary artery stenosis in a total of 66 CAD patients (age, >18 yr). All patients undergoing PCI for acute coronary syndrome and with stable CAD with risk factors (hypertension, hypercholesterolemia, active smoking, and diabetes) were eligible for inclusion. The exclusion criteria were as follows: 1) age greater than 80 yr; severe renal failure (creatinine level >2.5 mg/dL); active internal bleeding; known intolerance to aspirin, cilostazol, or clopidogrel; need for oral anticoagulation therapy; ST elevation within 12 hr of an onset of myocardial infarction onset; use of a IIb/IIIa glycoprotein inhibitor prior to screening; thrombocytopenia (platelet count <80,000/mL) or anemia (Hb <8.0 g/dL); and use of any investigational drug or device within 2 months prior to screening. Informed consent was obtained from all participants. At least 12 hr before coronary stenting, all patients were administered a loading dose of aspirin (300 mg), clopidogrel (300 mg), and cilostazol (200 mg). Blood samples were collected into vacuum tubes containing 3.2% sodium citrate just before coronary intervention.
Platelet-function tests
1) Light transmission aggregometry
Light transmission aggregometry (LTA) is the gold standard technique for measuring platelet aggregation [13] .
In this method, platelet aggregation is measured in response to a given agonist such as ADP or arachidonic acid (AA). In this study, platelet aggregation was induced by administering 0.5 mM AA and 10 mM ADP, and measured using a Chronolog impedance aggregometer (Chronolog Series 590; Probe and Co., Endingen, Germany). The result was expressed in terms of the maximal percent change in light transmittance from baseline values after the addition of an agonist, using plateletpoor plasma as reference.
2) VerifyNow assay
VerifyNow (Accumetrics, San Diego, CA, USA) is a light-transmission-based optical detection assay that measures the changes in the optical signal caused by platelet aggregation in cartridges containing fibrinogencoated beads. The results were expressed in terms of aspirin reaction units (ARU), P2Y12 reaction units (PRU), P2Y12% inhibition, and a baseline value [14] . were expressed in terms of platelet reactivity index (PRI) calculated by using the formula from the median fluorescence intensity of samples incubated with prostaglandin E1 (PGE1) or PGE1 and ADP [16] .
In the present study, blood samples for the LTA, VerifyNow, and multiplate analyses were obtained within 60-120 min after blood sampling in each study participant. The VASP phosphorylation state was determined within 24 hr in this study.
Characterization of aspirin and clopidogrel resistance
We characterized aspirin and clopidogrel resistance by applying reference values reported in the literature for each platelet-function test. The aspirin and clopidogrel resistances determined by performing LTA analysis were defined as 0.5 mM AA-induced platelet aggregation (%) more than 20% and 10 mM ADP-induced platelet aggregation (%) more than 50%, respectively [8, [17] [18] [19] [20] . The aspirin and clopidogrel resistances determined by using the VerifyNow assay were defined as an ARU of ≥550 U and P2Y12% inhibition of ≤20%, respectively [21] [22] [23] .
According to results of the analysis performed using the multiplate analyzer, the upper quintile of patients was defined as resistance. A PRI of ≥50% in VASP phosphorylation analysis was regarded as clopidogrel resistance [24] . 
Statistical methods
RESULTS
Sixty-six patients were recruited for the study. The demographic and angiographic data of the patients are shown in Table 1 The prevalence of aspirin and clopidogrel resistance resulted in remarkable variations, from 0% to 22.7% and from 9.1% to 48.5%, respectively (Table 2 platelet-function tests were expressed using the k statistic analysis (Table 3) . For clopidogrel resistance, the k statistic analysis values were 0.1-0.3.
DISCUSSION
In most studies, platelet function is measured using the LTA analysis, which is the gold standard technique.
The LTA analysis has some drawbacks such as the time required for the completion of the test (up to 4 hr), need for skilled technicians, and preparation of platelet-rich plasma, which is time consuming and susceptible to artifacts [25, 26] . Additionally, several agonists at different doses can be used in LTA, which may result in poor reproducibility [12] . Flow cytometer is another technique that is used to measure platelet function, and a common assay that uses flow cytometry is the VASP/P2Y12 assay.
However, this assay also has some limitations such as labor-intensive procedures and need for experienced technicians [27] . Because of these limitations associated with LTA and flow cytometry, point-of-care tests, including VerifyNow, PFA-100, and multiplate analyzer assays, have been developed. However, various platelet-function tests have been reported to showed great variability in platelet response, and several studies reported that the results of the various tests were clearly uninterchangeable with regard to the differences between resistant and sensitive patients [12, 26, 28] .
In this study, we aimed to simultaneously compare the was as low as reported in previous reports [19, 29] In this study, the prevalence of aspirin and clopidogrel resistances resulted in remarkable variations, from 0% to 22.7% and from 9.1% to 48.5%, respectively. An overview of the literature reveals that the prevalence of aspirin resistance is 0.4-83.3% [10] , whereas that of clopidogrel resistance has been reported to be between 0 and 44% [30] . However, the exact prevalence of aspirin and clopidogrel resistance in patients with CAD remains unclear and is dependent on the tests used. This was associated with different aspects of platelet function measured in various assays.
Lordkipanidze@ et al. [29] reported a study for the com- In CAD patients undergoing PCI, significant proportions of patients have aspirin and clopidogrel resistance [31, 32] . Despite standard antiplatelet therapy with aspirin and clopidogrel, up to 4.7% of the patients develop thrombotic stent occlusion, thereby suggesting inappropriate platelet inhibition due to antiplatelet resistance [33] .
Platelets are the key mediators in the pathophysiology of atherothrombotic disease. Platelet function tests have been used to monitor patient response to antiplatelet therapy [34] . Several studies suggest that low responsiveness to antiplatelet therapy, as measured in various platelet-function tests, correlates with high rates of incidences of ischemic events [34] [35] [36] [37] . However, it is questionable whether the resistance defined by various platelet-function tests is actually paralleled by the occurrence of adverse clinical events. Modifications in antiplatelet therapy according to type of resistance in platelet-function tests will reduce the incidence of ischemic events. In addition, we observed 2 cases of stent thrombosis in our study, but the patients were responders for all the platelet function tests that we used.
In this context, it might be considered a limitation of the our study that there was a difference in the dose of cilostazol administered for maintenance therapy in patients. Patients were randomized to receive either triple antiplatelet therapy (cilostazol, aspirin, and clopidogrel) or dual antiplatelet therapy (aspirin and clopidogrel) according to a computer-generated randomization list. This factor may influence the incidence of an ischemic event and results of platelet-function tests. After longterm administration of dual therapy, whether enhanced antiplatelet activity will be consistently maintained by the addition of cilostazol to dual antiplatelet therapy needs to be assessed. In this study, 2 patients of the in dual antiplatelet therapy group developed stent thrombosis. In addition, the determination of the optimal timing for drug efficacy testing is yet to be reported. In this study, all patients received a loading dose of aspirin and clopidogrel and cilostazol at least 12 hr before coronary stenting, and blood samples were collected just before coronary intervention. The response to clopidogrel during maintenance therapy has been shown to be correlated with the platelet reactivity after administration of a loading dose [5] . Motovska et al. [38] showed that the U at the time of undergoing PCI, was associated with increased risk of cardiovascular death and stent thrombosis at 6 months of follow-up [39] . The VASP/P2Y12 assay, which is performed using standardized kits, also lowers inter-observer dependence, can be performed in less than 1 hr, and affords increased stability of the blood sample that can be stored at room temperature for up to 24 hr before processing. With the development of the VASP/P2Y12 assay to more directly assess P2Y12
blockade, several studies showed a similar relationship between high PRI and adverse cardiovascular events, including stent thrombosis, after PCI [7, 24, 40] . In 
